• Haruhiko Kishima, Takufumi Yanagisawa, Yuko Goto, Satoru Oshino, Tomoyuki Maruo, Naoki Tani, Hui Ming Khoo, Koichi Hosomi, Masayuki Hirata, and Toshiki Yoshimine.
• Department of Neurosurgery, Osaka University Graduate School of Medicine, Suita, Japan.
• Neuromodulation. 2016 Aug 1; 19 (6): 650-4.

ObjectivesIntrathecal baclofen (ITB) therapy is an effective treatment for patients with severe spasticity. However, the effect of ITB therapy on respiratory function has not been reported in detail. In this study we quantitatively analyzed the effects of ITB on the respiratory function of patients with spastic tetraplegia.MethodsWe retrospectively reviewed 23 patients who were administrated ITB therapy from January 2009 to December 2012. Six of these 23 patients, who had spastic tetraplegia and were able to undergo spirometric testing, were included this study. The spasticity derived from cervical spinal cord injury in four patients and cerebral palsy (CP) in two patients. Patients' Ashworth Scale scores and spirometer measurements obtained before and 1-6 months after the start of ITB therapy were evaluated and compared.ResultsBefore ITB therapy, %FVC of all six patients was below 80%, and a restrictive respiratory disorder was diagnosed in five patients and a combined respiratory disorder in one patient. Ashworth Scale scores for both the lower and upper extremities improved significantly with ITB therapy. Forced vital capacity (FVC), %FVC, and forced expiratory volume at one sec also improved significantly with ITB therapy.ConclusionsRespiratory disorders were indeed present in our SCI and CP patients with spastic tetraplegia, and the respiratory function of these patients improved with ITB therapy. Our results suggest that ITB therapy is safe and efficacious in patients with spastic tetraplegia and respiratory dysfunction.© 2016 International Neuromodulation Society.

27 keywords...

hide…